Suchergebnisse - "Chung, H C"

PubPharm (193)

1

Integrated analysis of gut metabolome, microbiome, and exfoliome data in an equine model of intestinal injury

enthalten in: Microbiome | 2024

von Whitfield-Cargile, C. | Chung, H. | Coleman, M. | +8

2

Integrated analysis of gut metabolome, microbiome, and exfoliome data in an equine model of intestinal injury

enthalten in: Microbiome | 2024

von Whitfield-Cargile, C. | Chung, H. | Coleman, M. | +8

3

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma : MAHOGANY cohort A

enthalten in: ESMO open | 2022

von Catenacci, D. | Kang, Y. | Yoon, H. | +21

4

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Niu, J. | Maurice-Dror, C. | Lee, D. | +16

CommentIn: Ann Oncol. 2022 Feb;33(2):119-122. - PMID 34839015

5

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma

enthalten in: ESMO open | 2022

von Catenacci, D. | Chung, H. | Shen, L. | +4

6

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Shitara, K. | Özgüroğlu, M. | Bang, Y. | +15

CommentIn: Ann Oncol. 2021 Sep;32(9):1073-1074. - PMID 34216739

7

Effects of psychological behaviour management programme on dental fear and anxiety in children : A randomised controlled clinical trial

enthalten in: European journal of paediatric dentistry | 2020

von Song, J. | Chung, H. | Sohn, S. | +1

8

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140) : an open-label, multicentre, phase 1b study

enthalten in: The Lancet. Oncology | 2020

von Lee, M. | Ryoo, B. | Hsu, C. | +38

CommentIn: Lancet Oncol. 2020 Jun;21(6):740-741. - PMID 32502436

9

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer : interim results of a randomized, phase II trial (ATTRACTION-4)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Boku, N. | Ryu, M. | Kato, K. | +13

10

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Bang, Y. | Kang, Y. | Ng, M. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[20]